The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Andreas Engert

University Hospital of Cologne

Department of Internal Medicine I

Germany

[email]@uni-koeln.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University Hospital of Cologne, Department of Internal Medicine I, Germany. 1998 - 2012
  • Department of Internal Medicine I, Cologne University Hospital, 50924 Cologne, Germany;. 2012
  • Klinik I für Innere Medizin, Universitätsklinik Köln, Kerpener Strasse 62, 50931 Köln, Germany. 2003 - 2009
  • First Department of Internal Medicine, Coordination Center for Clinical Trials, and Department of Radiotherapy, University Hospital of Cologne, Germany. 2007

References

  1. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Král, Z., Fuchs, M., Hallek, M., Kanz, L., Döhner, H., Dörken, B., Engel, N., Topp, M., Klutmann, S., Amthauer, H., Bockisch, A., Kluge, R., Kratochwil, C., Schober, O., Greil, R., Andreesen, R., Kneba, M., Pfreundschuh, M., Stein, H., Eich, H.T., Müller, R.P., Dietlein, M., Borchmann, P., Diehl, V. Lancet (2012) [Pubmed]
  2. Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. von Tresckow, B., Plütschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M.S., Meissner, J., Zijlstra, J.M., Soekler, M., Stein, H., Eich, H.T., Mueller, R.P., Diehl, V., Borchmann, P., Engert, A. J. Clin. Oncol. (2012) [Pubmed]
  3. Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group. Borchmann, P., Haverkamp, H., Diehl, V., Cerny, T., Markova, J., Ho, A.D., Eich, H.T., Mueller-Hermelink, H.K., Kanz, L., Greil, R., Rank, A., Paulus, U., Smardova, L., Huber, C., Dörken, B., Nerl, C., Krause, S.W., Mueller, R.P., Fuchs, M., Engert, A. J. Clin. Oncol. (2011) [Pubmed]
  4. Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. Klimm, B., Franklin, J., Stein, H., Eichenauer, D.A., Haverkamp, H., Diehl, V., Fuchs, M., Borchmann, P., Engert, A. J. Clin. Oncol. (2011) [Pubmed]
  5. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. Engert, A., Plütschow, A., Eich, H.T., Lohri, A., Dörken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K.C., Wilhelm, M., Debus, J., Eble, M.J., Sökler, M., Ho, A., Rank, A., Ganser, A., Trümper, L., Bokemeyer, C., Kirchner, H., Schubert, J., Král, Z., Fuchs, M., Müller-Hermelink, H.K., Müller, R.P., Diehl, V. N. Engl. J. Med. (2010) [Pubmed]
  6. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. Engert, A., Josting, A., Haverkamp, H., Villalobos, M., Lohri, A., Sökler, M., Zijlstra, J., Sturm, I., Topp, M.S., Rank, A., Zenz, T., Vogelhuber, M., Nogova, L., Borchmann, P., Fuchs, M., Flechtner, H.H., Diehl, V. J. Clin. Oncol. (2010) [Pubmed]
  7. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dörken, B., Ludwig, W.D., Koch, P., Hänel, M., Pfreundschuh, M., Wilhelm, M., Trümper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Müller-Hermelink, H.K., Hasenclever, D., Löffler, M. J. Clin. Oncol. (2009) [Pubmed]
  8. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Engert, A., del Giglio, A., Bias, P., Lubenau, H., Gatzemeier, U., Heigener, D. Onkologie (2009) [Pubmed]
  9. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Engert, A., Griskevicius, L., Zyuzgin, Y., Lubenau, H., del Giglio, A. Leuk. Lymphoma (2009) [Pubmed]
  10. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Engert, A., Franklin, J., Eich, H.T., Brillant, C., Sehlen, S., Cartoni, C., Herrmann, R., Pfreundschuh, M., Sieber, M., Tesch, H., Franke, A., Koch, P., de Wit, M., Paulus, U., Hasenclever, D., Loeffler, M., Müller, R.P., Müller-Hermelink, H.K., Dühmke, E., Diehl, V. J. Clin. Oncol. (2007) [Pubmed]
  11. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Engert, A., Bredenfeld, H., Döhner, H., Ho, A.D., Schmitz, N., Berger, D., Bacon, P., Skacel, T., Easton, V., Diehl, V. Haematologica (2006) [Pubmed]
  12. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Dühmke, E., Müller-Hermelink, K., Diehl, V. J. Clin. Oncol. (2005) [Pubmed]
  13. Recombinant human erythropoietin in oncology: current status and further developments. Engert, A. Ann. Oncol. (2005) [Pubmed]
  14. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Schnell, R., Borchmann, P., Staak, J.O., Schindler, J., Ghetie, V., Vitetta, E.S., Engert, A. Ann. Oncol. (2003) [Pubmed]
  15. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Bohlius, J., Reiser, M., Schwarzer, G., Engert, A. Br. J. Haematol. (2003) [Pubmed]
  16. The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Engert, A., Sausville, E.A., Vitetta, E. Curr. Top. Microbiol. Immunol. (1998) [Pubmed]
 
WikiGenes - Universities